Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients ...

During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...

Ociperlimab is described as a humanised IgG1 monoclonal antibody with the potential to enhance T cell-mediated immune ...

Q4 2024 Earnings Call Transcript April 1, 2025 Operator: Hello and welcome to the AIM ImmunoTech Fourth Quarter and Full Year ...

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

Doug Aldrich, a former guitarist with Whitesnake, Dio and currently The Dead Daisies, recently provided an update on his health after announcing last year that he was battling throat cancer. Per ...

This did not call into question the value of the assets, quite the contrary, as OPM finalized the phase 1 healthy volunteers of OPM-101, with very good results, and prepared the REVERT study, for ...

TIGIT in particular has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody vibostolimab ...

BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...